In particular, the percentage of CD8+ T lymphocytes as well as the CD4+/CD8+ ratio and the polarization toward an anti-cancer T-helper response (Th1 vs. Th2), seem to correlate with better prognosis and improved response to ICIs in melanoma, breast, and lung cancers (15–17). Here, CD8A is linked to cancer.